Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases
S Sato, T Suzuki, T Chinen, H Yamaguchi… - Journal of …, 2024 - Springer
Background The real-world efficacy, prognostic factors, and adverse events of second-line
nivolumab monotherapy and subsequent third-line therapy for unresectable or metastatic …
nivolumab monotherapy and subsequent third-line therapy for unresectable or metastatic …
Can Immune Checkpoint Inhibitors Pave the New Way for “Conversion Surgery” in Unresectable Esophageal Cancer?
S Sato, H Shimada - Annals of Surgical Oncology, 2024 - Springer
Despite the widespread use of systemic chemotherapy, with or without radiation, as the
standard treatment for locally advanced unresectable or metastatic esophageal squamous …
standard treatment for locally advanced unresectable or metastatic esophageal squamous …